Summary
Background
We investigated the prognostic value of the preoperative lymphocyte-to-mononuclear ratio (LMR) and platelet-to-lymphocyte ratio (PLR) in a large cohort of patients with non-small cell lung cancer (NSCLC).
Methods
Clinical-pathological data from 507 NSCLC patients at Taizhou Hospital of Zhejiang Province between 2010 and 2016 were retrospectively evaluated. X-tile software was used to assess the optimal cutoff levels for LMR and PLR. Univariate and multivariate Cox regression models were used to assess the prognostic factors.
Results
The median follow-up duration after surgical resection was 34.5 months. Patients were stratified into 2 groups by LMR (2.6 and = 2.6) and PLR (179.6 and = 179.6). Our results revealed that lower LMR (HR = 3.163 (1.821–5.493), P = 0.000), age (HR = 2.252 (1.412–3.592), P = 0.001), T stage (HR = 3.749 (2.275–6.179), P = 0.000), N stage (HR = 3.106 (1.967–4.902), P = 0.000), and cut edge (HR = 3.830 (1.077–13.618), P = 0.038) were considered to be independent indicators for overall survival (OS) of NSCLC patients. For disease-free survival (DFS), age, sex, T stage, N stage, LMR and cut edge were verified to be independent prognostic factors in patients with NSCLC.
Conclusions
In the study cohort, reduced LMR was a robust independent predictor for both OS and DFS in patients with NSCLC who underwent surgical resection.
Objective: This study aims to evaluate the clinical application of preoperative prealbumin-to-fibrinogen ratio (PFR) in the clinical diagnosis and prognostic value of hepatocellular carcinoma (HCC) patients. Methods: The clinical and laboratory data of 269 HCC patients undergoing surgical treatment from January 2012 to January 2017 in Taizhou Hospital were retrospectively analyzed. The Cox regression model was used to analyze the correlation between PFR and other clinicopathologic factors in overall survival (OS) and disease-free survival (DFS). Results: Cox regression analysis showed that PFR (hazard ratios [HR] = 2.123; 95% confidence interval [95% CI], 1.271–3.547; P = 0.004)was independent risk factors affecting the OS of HCC patients. Furthermore, a nomogram was built based on these risk factors. The C indices statistics for the OS nomogram was 0.715. Conclusion: Nomograms based on PFR can be recommended as the correct and actual model to evaluate prognosis for patients with HCC.
Background: This study aimed to establish an effective prognostic nomogram for stage I non-small cell lung cancer (NSCLC) patients receiving surgery.Methods: Stage I NSCLC patients at Taizhou Hospital of Zhejiang Province from October 2010 to June 2014 were included. Clinical, pathological and laboratory variables ascertained before surgery were selected through least absolute shrinkage and selection operator and Cox regression analysis, and a nomogram model was established. The nomogram model was validated using stage I NSCLC patients from the same institution between July 2014 and December 2015. Results: Training cohort included 274 patients. From 46 potential predictors, the independent risk factors for Overall survival (OS) of patients with stage I NSCLC were age, CA125, and tumor diameter. The C index of the nomogram model was 0.759(95% confidence interval (CI),0.666–0.852). The area under the ROC curve of the nomogram was 0.776. The patients in the low-risk subgroup had significantly better survival than those in the high-risk subgroup (logrank, p < 0.001). The AUC in the validation cohort was 0.809, and the C index was 0.707(95% CI, 0.572-0.842).Conclusion: We developed a nomogram model that includes clinical, pathological and laboratory variables to predict the OS of stage I NSCLC patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.